— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.
— Total revenue stood at $1.96 million vs. $3.68 million expected.
— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.
— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.
— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.
— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Key highlights from Bank of America’s (BAC) Q4 2024 earnings results
Bank of America Corporation (NYSE: BAC) reported its fourth quarter 2024 earnings results today. Revenue, net of interest expense, was $25.3 billion, up 15% year-over-year. Net income was $6.7 billion,
US Bancorp (USB) Q4 profit rises on higher revenues, beats estimates
U.S. Bancorp (NYSE: USB) Thursday reported an increase in revenue and profit for the fourth quarter of 2024. Earnings also came in above analysts' forecasts. Total net revenue increased 3.7%
UnitedHealth Group (UNH) Q4 2024 Earnings: Key financials and quarterly highlights
UnitedHealth Group (NYSE: UNH) reported its fourth quarter 2024 earnings results today. Total revenues were $100.8 billion compared to $94.4 billion reported in the same period a year ago. Net